These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31663387)

  • 41. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 42. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
    Fung J; Wong T; Chok K; Chan A; Sin SL; Cheung TT; Dai WC; Ng K; Ng K; Man K; Seto WK; Lai CL; Yuen MF; Lo CM
    Transplantation; 2017 Oct; 101(10):2391-2398. PubMed ID: 28731907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years].
    Lin ZQ; Fang F; Guo ZF; Chen Q
    Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):592-8. PubMed ID: 18021533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
    Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV
    Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel orally available small molecule that inhibits hepatitis B virus expression.
    Mueller H; Wildum S; Luangsay S; Walther J; Lopez A; Tropberger P; Ottaviani G; Lu W; Parrott NJ; Zhang JD; Schmucki R; Racek T; Hoflack JC; Kueng E; Point F; Zhou X; Steiner G; Lütgehetmann M; Rapp G; Volz T; Dandri M; Yang S; Young JAT; Javanbakht H
    J Hepatol; 2018 Mar; 68(3):412-420. PubMed ID: 29079285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural history of chronic hepatitis B virus infection in childhood and efficacy of interferon therapy.
    Takano T; Tajiri H; Etani Y; Miyoshi Y; Tanaka Y; Brooks S
    Scand J Gastroenterol; 2015 Jul; 50(7):892-9. PubMed ID: 25861806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy.
    Igarashi T; Shimizu A; Igarashi T; Hanaoka K; Yoshizaki K; Shigemori T; Shimizu S; Komeichi H; Itoh Y
    J Nippon Med Sch; 2013; 80(5):387-95. PubMed ID: 24189358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.